A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for the Treatment of Patients with Progressive, Refractory Advanced Thyroid Carcinoma - the DUTHY Trial
Latest Information Update: 14 Nov 2024
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Carcinoma; Thyroid cancer
- Focus Therapeutic Use
- Acronyms DUTHY
Most Recent Events
- 11 Nov 2024 Status changed from active, no longer recruiting to discontinued. ( In compliance with current legislation applicable to Clinical Trials, following the instructions of the Spanish Agency for Medicines and Health Products.)
- 03 Oct 2024 Planned End Date changed from 1 Dec 2024 to 1 Dec 2025.
- 03 Oct 2024 Planned primary completion date changed from 1 Jul 2024 to 1 Jul 2025.